NEW YORK (GenomeWeb News) – Response Genetics today announced the execution of a provider contract with Blue Cross and Blue Shield of Illinois, providing the health plan's 7.4 million members coverage for the Los Angeles-based molecular diagnostics firm's tests.
Response Genetics offers molecular predictive tests for lung, colon, gastric, and melanoma cancers, as well as tests for detecting EGFR, KRAS, and other mutations. Its tests, the firm said, help physicians determine which treatments may be best for each individual patient.
In May the company joined the provider network of Blue Shield of California, its first contract with an affiliate of Blue Cross Blue Shield.